Table 1

Cohort demographics

RA+aTNF

RA+MTX

RA

Healthy Controls


N

61

70

33

97

Age, mean +/- SD years

55.4 +/- 12.3

58.4 +/-12.2

57.1 +/-13.8

39.8 +/- 13.6

% female

82%

77%

64%

63%

Disease duration < 1 year

5%

17%

45%

NA

Disease duration > 3 years

93%

60%

47%

NA

Adalimumab n (%)

9 (15)

NA

NA

NA

Infliximab n (%)

17 (28)

NA

NA

NA

Etanercept n (%)

35 (57)

NA

NA

NA

MTX n (%)

49 (80)

70 (100)

0 (0)

NA

MTX, dose +/- SD mg/wk

15.2 +/- 4.3

16.5 +/- 4.0

NA

NA

corticosteroid n (%)

18 (29.5)

26 (37.1)

10 (30.3)

NA

corticosteroid, dose +/- SD mg/d

5.5 +/- 3.5

4.9 +/- 2.0

10.3 +/-6.1

NA

ESR mean (range)

21 (4-70)

22 (2-83)

20 (2-74)

NA

HAQ mean (range)

0.71 (0.00-2.22)

0.73 (0.00-2.75)

0.46 (0.00-1.63)

NA

VAS mean (range) cm

2.8 (0.0-9.8)

3.3 (0.0-7.5)

2.8 (0.0-7.1)

NA

Morning stiffness mean (range) min

81 (0-780)

104 (0-1440)

59 (0-180)

NA

Race non Caucasian n (%)

8 (13)

6 (9)

2 (6)

12 (12)


ESR, erythrocyte sedimentation rate; HAQ, health assessment questionnaire; MTX, methotrexate; NA, not applicable; SD, standard deviation; VAS, visual analogue score.

Kobie et al. Arthritis Research & Therapy 2011 13:R209   doi:10.1186/ar3542

Open Data